Safety and efficacy of azacitidine in myelodysplastic syndromes

被引：25

作者：

Vigil, Carlos E. ^{[1
]}

Martin-Santos, Taida ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2010年 / 4卷

关键词：

Azacitidine; MDS; hypomethylating agents; MYELOID-LEUKEMIA; VALPROIC ACID; 5-AZACYTIDINE; TRANSPLANTATION; EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; METHYLATION; COMBINATION; ANTIGENS; CANCER;

D O I：

10.2147/DDDT.S3143

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.

引用

页码：221 / 229

页数：9

共 54 条

[1]

[Anonymous], 2009, VID AZ PACK INS

[2]

BELLET RE, 1974, CANCER CHEMOTH REP 1, V58, P217

[3] Azacitidine for the treatment of myelodysplastic syndrome [J].

Cataldo, Vince D. ;

Cortes, Jorge ;

Quintas-Cardama, Alfonso .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) :875-884

[4] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

[5] Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR) [J].

Coral, S ;

Sigalotti, L ;

Gasparollo, A ;

Cattarossi, I ;

Visintin, A ;

Cattelan, A ;

Altomonte, M ;

Maio, M .

JOURNAL OF IMMUNOTHERAPY, 1999, 22 (01) :16-24

[6] A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome [J].

Cutler, CS ;

Lee, SJ ;

Greenberg, P ;

Deeg, HJ ;

Pérez, WS ;

Anasetti, C ;

Bolwell, BJ ;

Cairo, MS ;

Gale, RP ;

Klein, JP ;

Lazarus, HM ;

Liesveld, JL ;

McCarthy, PL ;

Milone, GA ;

Rizzo, JD ;

Schultz, KR ;

Trigg, ME ;

Keating, A ;

Weisdorf, DJ ;

Antin, JH ;

Horowitz, MM .

BLOOD, 2004, 104 (02) :579-585

[7]

de Lima, 2008, BLOOD, V112, P1134

[8] A dose and schedule finding study of maintenance therapy with low-dose 5-azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk AML or MDS [J].

de Lima, Marcos ;

Padua, L. ;

Giralt, S. ;

Hosini, C. ;

Komanduri, K. ;

Qazilbash, M. ;

Shpall, E. J. ;

Thall, P. ;

Qureshi, S. ;

McCormick, G. ;

Tong, W. ;

Popat, U. ;

Soriano, A. ;

Champlin, R. ;

Garcia-Manero, G. .

BLOOD, 2007, 110 (11) :884A-885A

[9]

Fenaux P, 2007, BLOOD, V110, p250A

[10] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

← 1 2 3 4 5 6 →